Participated · Equity · Feb 2026

Anterior pairs advanced artificial intelligence with its "Forward Deployed Clinician" model, placing embedded clinicians alongside payer staff to ensure safe, accurate, and rapid AI adoption. The platform integrates with enterprise systems like HealthEdge’s GuidingCare and is already supporting organizations that collectively cover 50 million member lives. In live production, Anterior has delivered 99.24% independently validated clinical accuracy, cut review cycles by roughly 75%, and driven staff satisfaction above 90%. Since its June 2024 launch of a five-day average deployment model, the company has expanded deployments across major U.S. health plans, including Geisinger Health Plan and partners such as WNS-HealthHelp. Advisory bench strength now includes former VA Secretary David Shulkin, Peter Long of Blue Shield heritage, and ex-UnitedHealthcare executive William Golden. The new capital will fund additional clinical and operational use cases, deeper ecosystem integrations, and broader production rollouts. To date, Anterior has secured $64 million in total funding.

Participated · Series D · Jan 2026

Mews develops a unified hospitality operating system that combines property-management (PMS), point-of-sale (POS), revenue-management (RMS), housekeeping, and integrated payments into one cloud platform. Its tools automate routine tasks, allow hotels to manage and sell any type of space, and embed commerce directly into daily operations. In 2025 the company served 15,000 customers in 85 countries, supporting 132,000+ monthly active hoteliers and processing 42.3 million check-ins, with 3.2 million handled through its self-service Mews Kiosk. Platform Transaction Volume reached $19.7 billion and SaaS gross profit grew 55%, while its Mews Spaces feature generated $537 million in extra revenue for hoteliers. Recent acquisitions, including generative-AI analytics firm DataChat, underpin a strategy to infuse agent-driven AI across the stack. Future plans focus on deeper AI automation, expansion of Mews Payments and other fintech services, and continued geographic growth in North America, Europe, and new markets. The January 2026 funding round values Mews at $2.5 billion, giving it additional resources to accelerate product development and global scale.

Participated · Series D · Jan 2026

Founded in 2014 by Kai Eberhardt and Manuel Baumann, Oviva pairs a medical-device-certified mobile app with remote multidisciplinary care teams to provide evidence-based lifestyle and behavioural interventions for weight management and chronic illnesses. The platform’s embedded AI personalises treatment pathways, supports clinicians’ workflow, and maintains consistent quality at scale. Integrated into national reimbursement schemes such as Germany’s DiGA, the UK’s NHS, and Switzerland’s health system, Oviva removes long wait times and geographic barriers for patients. More than 1 million patients have already used the service, and 90+ clinical studies support its long-term efficacy. Unlike competitors such as Kry/Livi, HelloBetter, Omada Health, or Noom, Oviva focuses on reimbursed, weight-related and metabolic care in European public systems. With fresh capital, the company plans to extend its digital programmes to additional chronic indications, including hypertension and type 2 diabetes, to better manage comorbidities. The €200 million Series D provides significant resources for product expansion and deeper market penetration across Europe.

Participated · Equity · Oct 2025

Encube is a Stockholm-based startup developing a cloud platform that uses artificial intelligence to identify which design choices introduce manufacturing complexity and how to avoid them. Delivered through a browser interface, the software lets distributed hardware teams collaborate in real time, align on decisions, and explore a wider array of design options. Early pilots with large industrial firms and space-sector partners reportedly cut time-to-market by up to 50 %, lowered production costs by 20–30 %, and doubled engineering productivity. The system automates traditionally manual bottlenecks, embedding manufacturability and sustainability considerations at the earliest stages of product development. Encube was founded by former Sandvik executive Hugo Nordell (CEO) and Johnny Bigert, who previously held senior roles at Skype and Klarna. With fresh capital, the company plans to deepen its hardware-focused AI capabilities, expand partnerships, and scale commercial operations across Europe. The platform targets a market reshaped by onshoring, talent shortages, and stricter sustainability regulations, positioning Encube as a critical enabler of cost-efficient, low-carbon manufacturing.

Participated · Equity · Oct 2025

StratifAI is a precision oncology company founded in Berlin that applies artificial intelligence to identify prognostic and predictive biomarkers from multimodal clinical data. Its core product, the Polaris™ platform, fuses H&E histology with RNA-Seq gene expression to link spatial tumor signals directly to patient outcomes, speeding up biomarker discovery while lowering associated costs. The company is assembling a large multimodal reference dataset from collected tumor samples to continually expand its portfolio of spatial biomarkers. StratifAI’s first commercial test, Polaris™ Breast, assesses metastasis risk in early breast cancer and is currently undergoing regulatory review in the EU and the United States. Fresh capital is earmarked to complete clinical validation of Polaris™ Breast and to establish a scalable regulatory framework for clinical AI diagnostics. In parallel, the firm is deepening collaborations with oncology centers and pharmaceutical partners to build the clinical evidence required for guideline inclusion and routine practice. By leveraging growing digital pathology data, StratifAI aims to unlock a sizable, under-served market in cancer diagnostics and deliver more individualized and equitable care for patients with solid tumors.